Medexus Pharmaceuticals Inc.
TSX:MDP.TO · Toronto Stock Exchange
+$0.05 today
Vol 0.02M · Avg 0.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:MDP.TO · Revenue to Net Income
Key Ratios
Analysis
$99.4M of revenue converted into -$272.0K of net income for the selected period. Gross margin is 53.9% and net margin is -0.3%, showing how much revenue survives after costs and taxes. EPS is $-0.01, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.3M -4.2% | $113.1M +4.6% | $108.1M +40.9% | $76.7M -3.7% | $79.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $51.7M -3.3% | $53.5M +11.4% | $48.1M +23.9% | $38.8M +3.0% | $37.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $56.6M -4.9% | $59.5M -0.9% | $60.0M +58.3% | $37.9M -9.7% | $42.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 52.2% -0.4pp | 52.6% -2.9pp | 55.5% +6.1pp | 49.4% -3.3pp | 52.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $8.3M +2.7% | $8.0M +173.2% | $2.9M -49.9% | $5.9M +27.8% | $4.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.1M -5.9% | $38.4M -20.3% | $48.3M +9.6% | $44.0M +21.7% | $36.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $48.4M -0.7% | $48.7M -7.1% | $52.4M +4.2% | $50.3M +16.0% | $43.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $7.2M +23.6% | $5.8M -4.5% | $6.1M -1.0% | $6.1M -22.2% | $7.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $16.8M -12.8% | $19.3M +31.6% | $14.6M +0.7% | $14.5M +161.6% | -$23.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 15.5% -1.5pp | 17.1% +3.5pp | 13.5% -5.4pp | 19.0% +48.6pp | -29.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.2M -23.8% | $10.8M +41.8% | $7.6M +161.5% | -$12.4M -799.4% | -$1.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 7.6% -2.0pp | 9.5% +2.5pp | 7.0% +23.2pp | -16.1% -14.4pp | -1.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 -100.0% | $4.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.2M -38.7% | $13.4M -1.8% | $13.6M +11.3% | $12.2M +20.6% | $10.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$6.8M +36.5% | -$10.7M +15.5% | -$12.7M -247.9% | $8.6M +128.4% | -$30.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.4M +1258.5% | $106.0K +102.1% | -$5.0M -32.0% | -$3.8M +87.9% | -$31.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 1.3% +1.2pp | 0.1% +4.8pp | -4.7% +0.3pp | -5.0% +34.6pp | -39.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$807.0K -352.2% | $320.0K +105.1% | -$6.3M -565.5% | -$941.0K +70.9% | -$3.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $2.2M +1150.0% | -$214.0K -117.5% | $1.2M +142.4% | -$2.9M +89.8% | -$28.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 2.1% +2.3pp | -0.2% -1.3pp | 1.1% +4.9pp | -3.8% +31.7pp | -35.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +1037.5% | -$0 -111.9% | $0 +142.6% | -$0 +89.8% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +942.1% | -$0 -112.1% | $0 +141.4% | -$0 +89.8% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $25.8M +15.7% | $22.3M +11.7% | $20.0M +2.7% | $19.5M +28.0% | $15.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $26.5M +17.9% | $22.5M +9.6% | $20.5M +3.4% | $19.9M +30.7% | $15.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
iAnthus Capital Holdings, Inc.
IAN.CN
$69.73M
Decibel Cannabis Company Inc.
DB.V
$69.23M
Vext Science, Inc.
VEXT.CN
$61.92M
Planet 13 Holdings Inc.
PLTH.CN
$60.79M
BioNxt Solutions Inc.
BNXT.CN
$48.08M
C21 Investments Inc.
CXXI.CN
$43.91M
MariMed Inc.
MRMD.CN
$37.93M
The Cannabist Company Holdings Inc.
CBST.NE
$17.47M
InnoCan Pharma Corporation
INNO.CN
$14.17M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MDP.TO generate?
Medexus Pharmaceuticals Inc. (MDP.TO) reported $108.33M of revenue in fiscal 2025.
Is MDP.TO profitable?
Medexus Pharmaceuticals Inc. (MDP.TO) reported $2.25M of net income, with a net margin of 2.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.